Adenosine A2A receptor Inhibitors
2 drugsAbout Adenosine A2A receptor
The Adenosine A2A receptor is a G protein-coupled receptor activated by adenosine, a naturally occurring nucleoside. It plays a role in various physiological processes, making it relevant to multiple therapeutic areas.
Currently, there is no genetic evidence directly linking the A2A receptor to specific diseases. However, the existence of approved drugs suggests therapeutic potential.
Two FDA-approved drugs target the A2A receptor: LEXISCAN and NOURIANZ. Both are small molecules, with applications in cardiac stress testing and Parkinson's disease, respectively.
Strategic Insights
ℹ️ How we calculate- White space opportunity in ALS with only 1 trials.
Top Adenosine A2A receptor Drugs
ASTELLAS and KYOWA KIRIN are the companies with approved drugs.
The market is concentrated; new entrants may face challenges in gaining market share.
Adenosine A2A receptor Drug Modality Landscape
Modalities
Routes of Administration
Adenosine A2A receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could create differentiation.
Adenosine A2A receptor Clinical Trials 45 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 13 | 9 | 1 | 3 | 90% |
| Phase 2 | 10 | 6 | 3 | 1 | 67% |
| Phase 3 | 8 | 8 | 0 | 0 | 100% |
| Phase 4 | 14 | 12 | 1 | 1 | 92% |
Top Sponsors
By Modality
Top Conditions
Adenosine A2A receptor Drug Approval Timeline (2008 - 2019)
The first drug was approved in 2008, and the most recent in 2019, spanning 12 years.
The approval timeline suggests moderate interest; further innovation could revitalize the field.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 22 clinical trials targeting Adenosine A2A receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities